Session: 641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Translational Research, CLL, Diseases, Lymphoid Malignancies
Objectives. We evaluated the transcriptomes of NBC from people with MBL (NBC-MBL) and compared these to NBC of healthy controls (NBC-HC) and to MBL clonal B cells (Clonal-MBL). Also, we compared the transcriptomic profiles of CD5ˉ NBC-M-MBL, NBC-U-MBL, and NBC-HC.
Methods. PBMCs from 13 people with MBL (9 M-MBL, 4 U-MBL) and from 13 HC were FACS-isolated to obtain CD5+ clonal B cells (CD19+CD20DimCD5+Igκ+ or Igλ+) for MBL, and up to 4 B-cell fractions of NBC (CD19+CD20BrightCD5ˉ or CD5+/Igκ+ or Igλ+) for MBL and HC. Each cell fraction was >99% pure. In all, 76 cell fractions were collected, 34 from MBL and 42 from HC. RNA was sequenced using SMART-Seq v4 Ultra Low Input and HiSeq platform. DESeq2 was used to analyze RNA-seq data. PCA clustered samples based on transcriptomic variance. Differentially expressed genes (DEG) were obtained with adjusted P<0.05 and |FC|≥3. IPA identified relevant biological pathways. DEG protein products were validated by flow cytometry (FC) in 6 MBL (4 M-MBL and 2 U-MBL) and 8 HC.
Results. PCA of all B-cell fractions showed that NBC-HC, NBC-MBL, and Clonal-MBL fell into 3 distinct groups, indicating each group has distinct transcriptomes. Focusing on NBC from HC and from MBL based on IGHV-mutation status, 3 groups with a similar gradient were identified: NBC-HC > NBC-M-MBL > NBC-U-MBL (Fig 1), showing that NBC-HC differ from NBC-MBL and NBC differ within MBL based on IGHV-mutation types. Next, IPA was used to determine up- and down-regulated pathways (Fig 2). For CD5ˉ NBC-MBL from all MBL people vs. NBC-HC (C1; 1,704 DEG), IPA revealed activation of inhibitory (e.g., FcγRIIB, the most significant pathway, which can inhibit B-cell function) and stimulatory pathways (e.g., [1] S100 signaling, the second most significant pathway, which can trigger NF-κB activation; [2] phospholipase C signaling, the third most significant pathway, involved in cell survival and proliferation; and [3] IL-4, essential for B-cell survival and maturation). To discriminate contributions of NBC from M-MBL and U-MBL, IPA was first performed for CD5ˉ NBC-M-MBL vs. NBC-HC (C2; 1,086 DEG), showing 76% (13/17) of pathways significantly inhibited (e.g., HMGB1, TNFR1, IL17, and IL6). Notably, of the only 4 upregulated pathways, 2 were inhibitory, IL-10 signaling (the most significant pathway) and NFKBIE signaling. These findings suggest downregulation/anergy of NBC in M-MBL. Strikingly, the CD5ˉ NBC-U-MBL vs. NBC-HC comparison (C3; 10,959 DEG) showed that 100% (11/11) of IPA pathways were activated and stimulatory (e.g., S100 signaling), consistent with increased NBC-U-MBL proliferation and migration. FC analyses detected significant (P<0.05) protein overexpression of CD24, CD27, CD300a, CD32 and IL10RA in CD5ˉ NBC from all MBL vs. NBC-HC; CD27, CD300a and IL10RA overexpression in CD5ˉ NBC-M-MBL vs. NBC-HC; and CD27 and TLR10 overexpression in CD5ˉ NBC-U-MBL vs. NBC-HC, validating gene expression results.
Conclusions. PCA showed clear distinctions between NBC-MBL compared to NBC-HC, for both U-MBL and M-MBL. NBC-M-MBL appear to be functionally suppressed presumably due to IL-10 and NFKBIE signaling. In contrast, NBC-U-MBL appear to be stimulated through the S100 pathway. This activation of NBC-U-MBL seems paradoxical since in CLL there is greater immune suppression in U-CLL than M-CLL. Protein validation strengthens these findings.
Acknowledgments. GB was supported by Fundación Alfonso Martín Escudero.
Disclosures: Barrientos: BeiGene: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Jannsen: Consultancy; AbbVie: Consultancy. Rhodes: ADC Therapeutics: Consultancy; Epizyme: Consultancy, Research Funding; Loxo Oncology: Research Funding; Genetech: Consultancy; Abbvie: Consultancy, Research Funding; Jannsen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Beigene: Consultancy; AstraZeneca: Consultancy; Morphosys: Consultancy; Oncternal Pharmaceuticals: Research Funding; SeaGen: Honoraria; GenMab: Consultancy; Acerta: Research Funding; Velosbio: Research Funding.
See more of: Oral and Poster Abstracts